智通财经网·2025-08-19 00:10Core Viewpoint - Rongchang Biologics has entered into an agreement with Santen Pharmaceutical's subsidiary, Santen China, granting exclusive rights for the development, production, and commercialization of the RC28-E injection in several Asian markets, while retaining global rights outside these regions [1][2] Group 1: Agreement Details - Rongchang Biologics will receive a non-refundable upfront payment of 250 million RMB from Santen China [1] - The agreement includes potential milestone payments of up to 520 million RMB for development and regulatory achievements, and up to 525 million RMB for sales milestones [1] - Additionally, Rongchang Biologics will earn a tiered sales royalty based on product sales in the licensed regions, ranging from high single-digit to double-digit percentages [1] Group 2: Product and Market Impact - RC28-E injection is a dual-target fusion protein drug developed by Rongchang Biologics for treating ocular neovascular diseases [2] - The collaboration is expected to accelerate market access and patient coverage for RC28-E, significantly shortening the commercialization cycle [2] - This partnership aims to provide innovative and efficient solutions for the treatment of retinal diseases [2]